Form 4: Corcept Therapeutics Officer Sean Maduck Executes Stock Options and Sells Shares
SEC Form 4 Filing
Sean Maduck, President of Corcept Endocrinology, exercised stock options and sold shares of Corcept Therapeutics common stock on May 1st and 2nd, 2025, according to a Form 4 filing with the SEC.
Summary
- Sean Maduck, an officer of Corcept Therapeutics, executed stock options to purchase shares of common stock at a price of $5.05.
- He then sold those shares on the open market at prices ranging from $71.88 to $73.00 per share.
- The transactions occurred on May 1st and 2nd, 2025.
- Maduck sold 12,856 shares on May 1st and 26,554 shares on May 2nd.
- Following these transactions, Maduck directly owns 85,622 shares and indirectly owns 20,000 shares through Duckhill Capital, LLC and Sean and Molly Maduck Living Trust.
- The sales were conducted under a pre-arranged 10b5-1 trading plan adopted on September 5, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an officer. It doesn't inherently convey positive or negative sentiment, as it simply reports facts.
Industry Context
This filing is a routine disclosure of insider trading activity. It is common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like 10b5-1 plans, to manage their personal finances.
Comparison to Industry Standards
- Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into management's confidence in the company's future prospects.
- Companies like Amgen, Gilead Sciences, and Biogen are often compared to Corcept Therapeutics in terms of market capitalization and drug development pipelines.
- Comparing the frequency and magnitude of insider transactions at Corcept to these peers can provide a relative assessment of insider sentiment.
Stakeholder Impact
- The transactions could have a minor impact on shareholders, potentially creating downward pressure on the stock price due to the increased supply of shares in the market.
- However, the existence of a 10b5-1 plan suggests that these sales are pre-planned and not necessarily indicative of management's view of the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 09/05/2024 | 10b5-1 plan adopted by the Reporting Person |
| 09/03/2024 | Grant date of unvested restricted stock awards |
| 12/02/2024 | Grant date of unvested restricted stock awards |
| 03/03/2025 | Grant date of unvested restricted stock awards |
| 05/01/2025 | Date of stock option exercise and share sale |
| 05/02/2025 | Date of stock option exercise and share sale |
| 05/02/2026 | Expiration date of stock options |
| 05/05/2025 | Date of Form 4 filing |
Keywords
Form 4, insider trading, stock options, share sales, Sean Maduck, Corcept Therapeutics, CORT, 10b5-1 plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.